none of your business wrote:
>
> On Jul 21, 10:51 pm, Goomba > wrote:
> > Mark Thorson wrote:
> > > First, you'll need a complete list
> > > of the forbidden foods. Curry, tumeric,
> > > grapefruit, and yellow onions would certainly
> > > be on the list because they interefere with
> > > chemotherapy.
> >
> > Says who? Got a citation for that claim?
> > We always told patients to eat whatever they wanted if that is what they
> > wanted and their condition allowed. Many suffer ulcerations of their
> > oral cavity because of the way chemotherapy interferes with cell
> > replication. Epithelial cells in the mouth are very sensitive to this
> > and it often makes eating painful. So finding foods that nourish, yet
> > aren't difficult to eat are important. And yet everyones tolerance varies.
>
> I was on Abraxane 1x week and Carpoplatin 1x every 3 weeks. And for 2
> solid months, all I wanted to eat was Red Texas Grapefruits. 1-2 a
> day. And steak and lots of carbs. and I told the chemo nurses and the
> oncologist about every weird food craving I had and the answer was
> always "if that's what you want to eat and you feel ok, that's what
> you eat." beef cravings made sense, you need meat to build red blood
> cells. the only warning I got was not to eat soy except in very small
> quantities because my cancer was estrogen fed and soy is a phyto-
> estrogen. Otherwise, my experience with eating during cancer treatment
> was "eat what you can".

In other words, you know nothing of the medical
literature on this subject, and yet you have the
audacity to criticize someone who is familiar
with these issues. You are a fool.

In the case of grapefruit, it contains naringen,
which suppresses P-gp expression, thus increasing
the potency of chemotherapy drugs. You really
don't want to be increasing or decreasing the
potency of these drugs, because they have a low
therapeutic index, that is to say, the difference
between an effective dose and a toxic dose is low.
Modulators of drug clearance should be avoided,
so that the physician can titrate the dose.


Z Naturforsch C. 2009 Jan-Feb;64(1-2):109-16.
Modulation of anticancer drug-induced P-glycoprotein
expression by naringin.
Ali MM, Agha FG, El-Sammad NM, Hassan SK.
Biochemistry Department, Division of Genetic Engineering
and Biotechnology, National Research Centre, Cairo, Egypt.

Multidrug resistance (MDR) is a phenomenon that is often
associated with decreased intracellular drug accumulation in
the tumour cells of a patient, resulting from enhanced drug
efflux. It is often related to the overexpression of
P-glycoprotein (P-gp) on the surface of tumour cells,
thereby reducing drug cytotoxicity. In the present study,
naringin (the predominant flavonone found in grapefruit and
other related citrus species) was tested for its potential
ability to modulate the expression of P-gp in a short-term
animal bioassay, in comparison with verapamil (a calcium
channel blocker and positive MDR reversal agent). Western
blot analysis showed that pre-treatment by i.p.
administration of 5 mg naringin/kg body weight for
3 consecutive days prior to doxorubicin (the most common
used anticancer drug which induces MDR) administration was
able to significantly lower the P-gp expression reaching
nearly the level of animals treated with verapamil. Moreover,
pre-treatment with naringin prior to doxorubicin increased
the sensitivity to the drug. Naringin inhibited the
doxorubicin-stimulated ATPase activity demonstrating that
naringin may interact directly with the transporter. In
addition, the results demonstrated that induction of both
glutathione (GSH) and glutathione-S-transferase (GST) by
doxorubicin is consistent with an increased ATP-dependent
doxorubicin transport. Thus, naringin seems to modulate
the in vivo expression of P-gp. In summary, the present
study describes the dual modulation of P-gp expression and
function by the flavonoid naringin, which may be an
attractive new agent for the chemosensitization of cancer
cells.